Dataset Information

Global quantification of pulmonary artery atherosclerosis using 18F-sodium fluoride PET/CT in at-risk subjects.

ABSTRACT: The goal of this study was to assess pulmonary artery calcification in healthy controls and subjects with suspicion of stable angina pectoris through the usage of quantitative 18F-sodium fluoride positron emission tomography/computed tomography (NaF-PET/CT). We hypothesized that these 'at-risk subjects' would demonstrate increase pulmonary artery NaF uptake compared to healthy controls. Retrospectively, 15 healthy controls were compared to 15 at-risk subjects, all of whom underwent full-body NaF-PET/CT scans. The healthy controls and at-risk patients were all randomly sampled from larger datasets. The two sampled groups were male-dominated and similar in age. The global mean standard uptake value (SUVmean), the max standard uptake value (SUVmax), and the mean target-to-background ratio (TBRmean) were acquired through mapping of regions of interest (ROI's) around the pulmonary artery of the subjects. A two-tailed Mann-Whitney U test was used to determine the significance of difference between the two groups. For global SUVmean (0.79 compared to 0.58), global TBRmean (1.15 compared to 0.93), and global SUVmax (1.78 compared to 1.60), the NaF uptake was significantly higher in the at-risk patients compared to the controls (all P<0.05). NaF-PET/CT is a suitable imaging modality for quantification of molecular calcification in the pulmonary artery. Additionally, the connection between atherosclerosis and the risk factor of angina pectoris is further reinforced. We believe that future studies are needed to validate our proof-of-concept, and better confirm the clinical future of NaF-PET/CT as a tracer of atherosclerotic plaques.

SUBMITTER: Zhang V

PROVIDER: S-EPMC7218698 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Global quantification of pulmonary artery atherosclerosis using <sup>18</sup>F-sodium fluoride PET/CT in at-risk subjects.

Zhang Vincent V Borja Austin J AJ Rojulpote Chaitanya C Padmanabhan Sayuri S Patil Shivaraj S Gonuguntla Karthik K Revheim Mona-Elisabeth ME Werner Thomas J TJ Høilund-Carlsen Poul F PF Alavi Abass A

American journal of nuclear medicine and molecular imaging 20200415 2

The goal of this study was to assess pulmonary artery calcification in healthy controls and subjects with suspicion of stable angina pectoris through the usage of quantitative <sup>18</sup>F-sodium fluoride positron emission tomography/computed tomography (NaF-PET/CT). We hypothesized that these 'at-risk subjects' would demonstrate increase pulmonary artery NaF uptake compared to healthy controls. Retrospectively, 15 healthy controls were compared to 15 at-risk subjects, all of whom underwent fu ...[more]

PMID: 32419980

Similar Datasets

Project description:The purpose of this study was to compare the diagnostic performance of 18F-DCFBC PET/CT, a first-generation 18F-labeled prostate-specific membrane antigen (PSMA)-targeted agent, and 18F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Methods: Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to 4 PET/CT scans. All patients completed baseline 18F-DCFBC PET/CT and 18F-NaF PET/CT scans, and 23 patients completed follow-up imaging, with a median follow-up interval of 5.7 mo (range, 4.2-12.6 mo). Lesion detection was compared across the 2 PET/CT agents at each time point. Detection and SUV characteristics of each PET/CT agent were compared with serum prostate-specific antigen (PSA) levels and treatment status at the time of baseline imaging using nonparametric statistical testing (Spearman correlation, Wilcoxon rank). Results: Twenty-six patients had metastatic disease detected on 18F-NaF or 18F-DCFBC at baseline, and 2 patients were negative on both scans. Three patients demonstrated soft tissue-only disease. Of 241 lesions detected at baseline, 56 were soft-tissue lesions identified by 18F-DCFBC only and 185 bone lesions detected on 18F-NaF or 18F-DCFBC. 18F-NaF detected significantly more bone lesions than 18F-DCFBC (P < 0.001). Correlation of PSA with patient-level SUV metrics was strong in 18F-DCFBC (? > 0.5, P < 0.01) and poor in 18F-NaF (? < 0.3, P > 0.1). When PSA levels were combined with treatment status, patients with below-median levels of PSA (<2 ng/mL) on androgen deprivation therapy (n = 11) demonstrated more lesions on 18F-NaF than 18F-DCFBC (P = 0.02). In PSA greater than 2 ng/mL, patients on androgen deprivation therapy (n = 8) showed equal to or more lesions on 18F-DCFBC than on 18F-NaF. Conclusion: The utility of PSMA-targeting imaging in metastatic prostate cancer appears to depend on patient disease course and treatment status. Compared with 18F-NaF PET/CT, 18F-DCFBC PET/CT detected significantly fewer bone lesions in the setting of early or metastatic castrate-sensitive disease on treatment. However, in advanced metastatic castrate-resistant prostate cancer, 18F-DCFBC PET/CT shows good concordance with NaF PET/CT.

Project description:PURPOSE:We examined the literature to elucidate the role of 18F-sodium fluoride (NaF)-PET in atherosclerosis. METHODS:Following a systematic search of PubMed/MEDLINE, Embase, and Cochrane Library included articles underwent subjective quality assessment with categories low, medium, and high. Of 2811 records, 1780 remained after removal of duplicates. Screening by title and abstract left 41 potentially eligible full-text articles, of which 8 (about the aortic valve (n = 1), PET/MRI feasibility (n = 1), aortic aneurysms (n = 1), or quantification methodology (n = 5)) were dismissed, leaving 33 published 2010-2012 (n = 6), 2013-2015 (n = 11), and 2016-2018 (n = 16) for analysis. RESULTS:They focused on coronary (n = 8), carotid (n = 7), and femoral arteries (n = 1), thoracic aorta (n = 1), and infrarenal aorta (n = 1). The remaining 15 studies examined more than one arterial segment. The literature was heterogeneous: few studies were designed to investigate atherosclerosis, 13 were retrospective, 9 applied both FDG and NaF as tracers, 24 NaF only. Subjective quality was low in one, medium in 13, and high in 19 studies. The literature indicates that NaF is a very specific tracer that mimics active arterial wall microcalcification, which is positively associated with cardiovascular risk. Arterial NaF uptake often presents before CT-calcification, tends to decrease with increasing density of CT-calcification, and appears, rather than FDG-avid foci, to progress to CT-calcification. It is mainly surface localized, increases with age with a wide scatter but without an obvious sex difference. NaF-avid microcalcification can occur in fatty streaks, but the degree of progression to CT-calcification is unknown. It remains unknown whether medical therapy influences microcalcification. The literature held no therapeutic or randomized controlled trials. CONCLUSION:The literature was heterogeneous and with few clear cut messages. NaF-PET is a new approach to detect and quantify microcalcification in early-stage atherosclerosis. NaF uptake correlates with cardiovascular risk factors and appears to be a good measure of the body's atherosclerotic burden, potentially suited also for assessment of anti-atherosclerotic therapy.

Project description:Our aim was to evaluate the interobserver agreement in 18F-sodium fluoride (NaF) PET/CT for the detection of bone metastases in patients with prostate cancer (PCa). Methods: 18F-NaF PET/CT scans were retrieved from all patients who participated in 4 recent prospective trials. Two experienced observers independently evaluated the 18F-NaF PET/CT scans on a patient level using a 3-category scale (no bone metastases [M0], equivocal for bone metastases, and bone metastases present [M1]) and on a dichotomous scale (M0/M1). In patients with no more than 10 lesions, the location and number of lesions were recorded. On a patient level, the diagnostic performance was calculated using a sensitivity analysis, in which equivocal lesions were handled as M0 as well as M1. Results: 18F-NaF PET/CT scans from 219 patients with PCa were included, of whom 129 patients were scanned for primary staging, 67 for biochemical recurrence, and 23 for metastatic castration-resistant PCa. Agreement between the observers was almost perfect on a patient level (3-category unweighted ? = 0.83 ± 0.05, linear weighted ? = 0.90 ± 0.06, and dichotomous ? = 0.91 ± 0.07). On a lesion level (dichotomous scale), the observers agreed on the number and location of bone metastases in 205 (93.6%) patients. In the remaining 14 patients, the readers disagreed on the number of lesions in 13 patients and the location of bone metastases in 1 patient. A final diagnosis of bone metastases was made for 211 of 219 patients. The sensitivity ranged from 0.86 to 0.92, specificity from 0.83 to 0.97, positive predictive value from 0.70 to 0.93, and negative predictive value from 0.94 to 0.96. Conclusion: The interobserver agreement on 18F-NaF PET/CT for the detection of bone metastases in patients with PCa was very high among trained observers, both on a patient level and on a lesion level. Moreover, the diagnostic performance of 18F-NaF PET/CT was satisfactory, rendering 18F-NaF PET/CT a robust tool in the diagnostic armamentarium.

Dataset Information

Global quantification of pulmonary artery atherosclerosis using 18F-sodium fluoride PET/CT in at-risk subjects.

Publications

Global quantification of pulmonary artery atherosclerosis using <sup>18</sup>F-sodium fluoride PET/CT in at-risk subjects.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets